Please try another search
Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
Name | Age | Since | Title |
---|---|---|---|
Francois Thomas | 67 | 2022 | Censor |
Karen Linehan | 65 | 2022 | Independent Director |
Pier Vincenzo Piazza | 63 | 2017 | CEO & Director |
Irina Staatz-Granzer | 64 | 2022 | Independent Director |
Brahim Guetarni | 53 | 2021 | Director |
Keith Humphreys | - | - | Member of Scientific Advisory Board |
Robert C. Malenka | - | - | Chairman of the Scientific Advisory Board |
Karina Hansen | 51 | 2022 | Independent Director |
Daniele Piomelli | - | - | Member of Scientific Advisory Board |
Markus Heilig | - | - | Member of Scientific Advisory Board |
Anders Gersel Pedersen | 73 | 2020 | Independent Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review